Annexon Reports Fourth Quarter and Year-End 2023 Financial R

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global...

Related Keywords

Brisbane , Queensland , Australia , Joyce Allaire , Sheryl Seapy , Nasdaq , International Guillain Barr , Securities Exchange , Clinical Program Updates , European Medicines Agency , Annexon Inc , Drug Administration , Pivotal Phase , Second Quarter , Geographic Atrophy , Primary Outcome Measure , Proof Of Concept Data , Classical Pathway Expected , Second Half , Balance Sheet , Cash Equivalents , Short Term Investments , Anticipated Runway , Douglas Love , Syndrome Outcomes Study , Biologics License Application , Fast Track , Priority Medicine , Cold Agglutinin Disease , Amyotrophic Lateral Sclerosis , Full Year , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports , Private Securities Litigation Reform Act , Consolidated Statements , Markets ,